PB0048 - Genetic variants and biological markers of coagulation and inflammation to predict the survival outcome upon SARS-CoV-2 infection in a cohort of patients from the first wave of COVID-19 in Argentina

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

Federico Aranda

Dr
Hospital de Infecciosas F. J. Muñiz
Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
SP

Silvia Perés

Dr
Hospital de Infecciosas F. J. Muñiz
Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
EC

Eleonora Cunto

MD
Hospital Of Infectious Diseases "Dr. Francisco J. Muñiz"
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
VC

Viviana Chediack

MD
Hospital Of Infectious Diseases "Dr. Francisco J. Muñiz"
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
MP

Mirta Peralta

MD
Hospital Of Infectious Diseases "Dr. Francisco J. Muñiz"
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
AB

Andrea Bocassi

Dr
Hospital de Infecciosas F. J. Muñiz
Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
JV

Jennifer Valero

Biochemist
Hospital Of Infectious Diseases "Dr. Francisco J. Muñiz"
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
MS

María Paula Svencionis

Biochemist
Hospital Prof. Dr. Luis Güemes de Haedo
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
JC

Julián Chamorro

Dr
Hospital de Infecciosas F. J. Muñiz
Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
TR

Tamara Rubilar

Dr
Laboratorio de Química de Organismos Marinos, Instituto Patagónico del Mar, Universidad Nacional de la Patagonia San Juan Bosco (UNPSJB) and CESIMAR-CONICET
Puerto Madryn, Chubut, Argentina
AC

Augusto Crespi

Dr.
Laboratorio de Química de Organismos Marinos, Instituto Patagónico del Mar, Universidad Nacional de la Patagonia San Juan Bosco (UNPSJB) and CESIMAR-CONICET
Puerto Madryn, Chubut, Argentina

Presenting Author(s)

Gabriela F. de Larrañaga, PhD

Dr.
Hospital de Infecciosas F. J. Muñiz
Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

Background: The severe clinical conditions and fatal outcomes resulting from SARS-CoV-2 infection have been associated with increased inflammatory and hypercoagulability processes, where an interplay between different comorbidities and genetic factors would be directly involved in the poor prognosis.

Aims: To study the association of different genetic variants, clinical variables and biological markers involved in inflammation and coagulation with the survival outcome of COVID-19.

Methods: 204 unvaccinated COVID-19 confirmed patients were grouped and compared according to their survival outcome. Inflammatory and hemostatic variables measured upon hospital admission, different clinical variables and the genotypic distributions of the genetic variants Factor II20210A (II20210A), Factor V Leiden (FVL), Fibrinogen Gamma 10034C>T (FGG10034C/T), Factor XI7872C>T (FXI7872C/T) and rs11385942 were compared between patients that either died (n=63) or survived (n=141). Differences between continuous variables were analyzed by either a t-test or a U-Mann Whitney test and differences in genotypic distributions were studied by a Chi-square test. Cut off values were set for continuous variables significantly associated with a fatal outcome and their Odds Ratios (OR) of association were calculated through univariate logistic regression.

Results: The group of patients who died were significantly older, had a higher BMI index and presented with a lower platelet count, lower lymphocytes levels, higher levels of leukocytes and neutrophils, a higher neutrophils/lymphocytes ratio and higher levels of D-dimer, Ferritin and LDH than survivors. No differences were observed in the genotypic distributions of the genetic variants studied between both groups.

Conclusion(s): In agreement with previous studies, age, obesity, and the levels of different hematological and plasmatic markers upon hospital admission would be useful predictors of a fatal outcome in COVID-19 patients. Despite the typical exacerbation of inflammation/coagulation in severe COVID-19, no association was found between the carriage of any of the proinflammatory/prothrombotic genetic variants studied and a higher risk of dying.